ALT
Altimmune, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.49
P/S
7189.74
EV/EBITDA
-3.20
DCF Value
$0.08
FCF Yield
-23.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-36387.8%
Operating Margin
-230461.0%
Net Margin
-214861.0%
ROE
-49.4%
ROA
-31.5%
ROIC
-35.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $26.0K | $-27.4M | $-0.27 |
| FY 2025 | $41.0K | $-88.1M | $-1.00 |
| Q3 2025 | $5.0K | $-19.0M | $-0.21 |
| Q2 2025 | $5.0K | $-22.1M | $-0.27 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.34
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.